Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News

More Details From China's Negative Results In Lancet

Executive Summary

AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.

You may also be interested in...



Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance

EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel